CAPTRUST Financial Advisors
MIRM icon

CAPTRUST Financial Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-300
Closed -$6K – 3246
2022
Q2 		$6K Hold
300
– – ﹤0.01% 4007
2022
Q1 		$7K Hold
300
– – ﹤0.01% 3976
2021
Q4 		$5K Hold
300
– – ﹤0.01% 4079
2021
Q3 		$6K Hold
300
– – ﹤0.01% 3877
2021
Q2 		$5K Buy
+300
New +$5.38K ﹤0.01% 3866

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CAPTRUST Financial Advisors's MIRM Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q3 2022, closing a stake of 300 shares — an estimated $6K sold.

CAPTRUST Financial Advisors first reported a position in MIRM in Q2 2021 and held it in 5 quarters. The position peaked at $7K in Q1 2022. 112 funds tracked by Wall St. Rank hold MIRM as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Mirum Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 300 Mirum Pharmaceuticals shares in Q3 2022, an estimated $6K.
  • CAPTRUST Financial Advisors first reported a position in Mirum Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's Mirum Pharmaceuticals position peaked at $7K in Q1 2022.
  • 112 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.